The Food and Drug Administration (FDA) has granted Orphan Drug designation to BA-102 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder linked to autism.

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

When leveraged to their appropriate context and strengths, under the care of an oncologist, cancer-related apps can actually strengthen the bond with the physician and care team, while empowering the ...

These HHS staffing cuts, 20,000, obviously they are completely nuts,” Wendell Primus, who worked at the ASPE during the Clinton administration.

The plan would cut tens of billions of dollars from federal health spending and move many already existing agencies into a new department called the Administration for a Healthy America.

All the scientists were fired from the only STI lab in the US that tested how well antibiotics were working against drug-resistant gonorrhea strains.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Cytisinicline treatment significantly increased the odds of smoking cessation and reduced nicotine cravings compared with placebo. Cytisinicline significantly increased the likelihood of quitting and ...

NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.